So we do know from first-line therapy with immunotherapy that 80% of those patients will fail therapy and the great majority of them only in a few months. So it still means that we are still at a loss in terms of what is the best option of treatment for patients with head and neck cancer when it’s recurrent or metastatic. And especially after immunotherapy, there is currently no trial that has proven that anything would be superior to single agent chemotherapy like Paclitaxel or even Methotrexate...
So we do know from first-line therapy with immunotherapy that 80% of those patients will fail therapy and the great majority of them only in a few months. So it still means that we are still at a loss in terms of what is the best option of treatment for patients with head and neck cancer when it’s recurrent or metastatic. And especially after immunotherapy, there is currently no trial that has proven that anything would be superior to single agent chemotherapy like Paclitaxel or even Methotrexate. So it still leaves a population for which there is a very high medical need for which there needs to be a lot of research and more agents being evaluated in that setting specifically.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
